Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial by Neil Solomons, Ian N Bruce, Paul Emery, Caroline Gordon, Edward Vital, David Jayne, David Isenberg, Neil McHugh, Miriam Wittmann, Stephen Young, John Reynolds, Niels Peek, Mark Lunt, Li Su, Sean Gavan, Katherine Payne, Michael Ehrenstein, Vern Farewell, Timothy Vyse, Marina Botto, David Lester Morris, D D’Cruz, Nophar Geifman, Angela Midgley, Matt Truman, Stephen McDonald, Sean Yiu, Laura Lisk, Gillian Armitt, Jennifer Prattley, Narges Azadbakht, Angela Papazian, Helen Le Sueur, Carmen Farrelly, Clare Richardson, Zunnaira Shabbir, Lauren Hewitt, Matthew Pickering, Elizabeth Lightstone, Alyssa Gilmore, Michael Beresford, Christian Hedrich, Jenna Gritzfeld, Mariea Parvaz, Jane Dunnage, Jane Batchelor, E Holland, Pauline Upsall

Get full text